Debt-to-equity of Immunome Inc. from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Immunome Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • Immunome Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 15%, a 8.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Immunome Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 15% -1% -8.7% 30 Sep 2025
Q2 2025 17% -12% -42% 30 Jun 2025
Q1 2025 19% -25% -57% 31 Mar 2025
Q4 2024 19% -103% -84% 31 Dec 2024
Q3 2024 17% -333% -95% 30 Sep 2024
Q2 2024 29% -100% -78% 30 Jun 2024
Q1 2024 43% -26% -37% 31 Mar 2024
Q4 2023 122% +91% +294% 31 Dec 2023
Q3 2023 350% +324% +1264% 30 Sep 2023
Q2 2023 129% +108% +512% 30 Jun 2023
Q1 2023 69% +54% +350% 31 Mar 2023
Q4 2022 31% +18% +143% 31 Dec 2022
Q3 2022 26% +16% +161% 30 Sep 2022
Q2 2022 21% -5% -21% 30 Jun 2022
Q1 2022 15% 31 Mar 2022
Q4 2021 13% 31 Dec 2021
Q3 2021 10% 30 Sep 2021
Q2 2021 27% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.